TY - JOUR
T1 - Allotype analysis to determine the origin of cytomegalovirus immunoglobulin-G after allogeneic stem cell transplantation
AU - Yamazaki, R.
AU - Tanaka, Y.
AU - Nakasone, H.
AU - Sato, M.
AU - Terasako-Saito, K.
AU - Sakamoto, K.
AU - Akahoshi, Y.
AU - Nakano, H.
AU - Ugai, T.
AU - Yamasaki, R.
AU - Wada, H.
AU - Ishihara, Y.
AU - Kawamura, K.
AU - Ashizawa, M.
AU - Kimura, S. I.
AU - Kikuchi, M.
AU - Kako, S.
AU - Kanda, J.
AU - Tanihara, A.
AU - Nishida, J.
AU - Kanda, Y.
N1 - Publisher Copyright:
© 2014 John Wiley & Sons A/S.
PY - 2014/12/1
Y1 - 2014/12/1
N2 - Background: Cytomegalovirus (CMV) reactivation still remains a major problem following allogeneic hematopoietic stem cell transplantation (HSCT). Patients and methods: In this study, we analyzed an immunoglobulin allotype, IgG1m(f), in CMV-seropositive HSCT recipients and their donors to distinguish donor-derived antibody from recipient-derived antibody. Eight donor-recipient pairs were informative regarding the appearance of donor-derived immunoglobulin-G (IgG), as the recipients were homozygous null for the IgG1m(f) allotype and the donors were IgG1m(f) positive. In these patients, total IgG, IgM, and allotype-specific IgG against CMV were measured by enzyme-linked immunosorbent assay. All subjects were monitored for at least 9 months after HSCT with (n = 5) or without (n = 3) CMV reactivation. Results: Donor-derived CMV IgG tended to be elevated earlier in patients with CMV-seropositive donors than in those with CMV-seronegative donors. In 1 patient with a CMV-negative donor, donor-derived CMV IgG was not detected until late CMV reactivation. In 3 patients without CMV reactivation, donor-derived CMV IgG was also elevated within 1-6 months after HSCT. Conclusion: In conclusion, the CMV serostatus of the donor may be related to the timing of the appearance of donor-derived CMV IgG and the reconstitution of humoral immunity against CMV, regardless of the CMV antigenemia level after HSCT.
AB - Background: Cytomegalovirus (CMV) reactivation still remains a major problem following allogeneic hematopoietic stem cell transplantation (HSCT). Patients and methods: In this study, we analyzed an immunoglobulin allotype, IgG1m(f), in CMV-seropositive HSCT recipients and their donors to distinguish donor-derived antibody from recipient-derived antibody. Eight donor-recipient pairs were informative regarding the appearance of donor-derived immunoglobulin-G (IgG), as the recipients were homozygous null for the IgG1m(f) allotype and the donors were IgG1m(f) positive. In these patients, total IgG, IgM, and allotype-specific IgG against CMV were measured by enzyme-linked immunosorbent assay. All subjects were monitored for at least 9 months after HSCT with (n = 5) or without (n = 3) CMV reactivation. Results: Donor-derived CMV IgG tended to be elevated earlier in patients with CMV-seropositive donors than in those with CMV-seronegative donors. In 1 patient with a CMV-negative donor, donor-derived CMV IgG was not detected until late CMV reactivation. In 3 patients without CMV reactivation, donor-derived CMV IgG was also elevated within 1-6 months after HSCT. Conclusion: In conclusion, the CMV serostatus of the donor may be related to the timing of the appearance of donor-derived CMV IgG and the reconstitution of humoral immunity against CMV, regardless of the CMV antigenemia level after HSCT.
KW - Cytomegalovirus
KW - Hematopoietic stem cell transplantation
KW - Humoral immunity
KW - Immunoglobulin allotypes
UR - http://www.scopus.com/inward/record.url?scp=84920124373&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84920124373&partnerID=8YFLogxK
U2 - 10.1111/tid.12304
DO - 10.1111/tid.12304
M3 - Article
C2 - 25367140
AN - SCOPUS:84920124373
SN - 1398-2273
VL - 16
SP - 904
EP - 913
JO - Transplant Infectious Disease
JF - Transplant Infectious Disease
IS - 6
ER -
